Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Takeda G-protein-coupled receptor 5 and farnesoid X receptor agonists for diabetes treatment: a patent review and clinical advancements (2015-present).

Expert opinion on therapeutic patents·2026
Same author

An integrated in silico approach to identify pyridine-based AChE and BChE inhibitors for Alzheimer's disease.

Computers in biology and medicine·2026
Same author

Equilibrium and non-equilibrium thermodynamics in drug repurposing: Machine learning-guided discovery of high-affinity WEE1 kinase inhibitors.

Journal of molecular graphics & modelling·2026
Same author

Advancements in Gene Delivery using Nucleic Acid Loaded Nanoparticles for Region Specific Delivery in Alzheimer's Disease.

Molecular neurobiology·2026
Same author

Microplastic-associated pollutants in prostate carcinogenesis and plant-based chemo-preventive strategies.

Drug and chemical toxicology·2026
Same author

Oxadiazole derivatives as potent androgen receptor inhibitors: Design, synthesis, and anticancer evaluation.

Bioorganic chemistry·2025

Related Experiment Video

Updated: May 16, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Targeting Chemo-resistance Mechanisms In Triple-negative Breast Cancer: A Review.

Vanktesh Kumar1, Pankaj Wadhwa1

  • 1Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Jalandhar, Punjab, IN 144411, India.

Mini Reviews in Medicinal Chemistry
|May 15, 2026
PubMed
Summary

Triple-Negative Breast Cancer (TNBC) is aggressive and hard to treat due to chemoresistance. This review explores resistance mechanisms and novel therapies, including natural products, to improve treatment outcomes.

Keywords:
ABC transporterADB-riboseOlaparibTriple negative breast cancerantibody-drug conjugates.chemoresistancetumor

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Experiment Videos

Last Updated: May 16, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-Negative Breast Cancer (TNBC) presents significant therapeutic challenges due to its aggressive nature and high chemoresistance.
  • Current targeted therapies like PARP inhibitors and ADCs show limited long-term efficacy due to acquired resistance.

Purpose of the Study:

  • To review the molecular and cellular mechanisms underlying intrinsic and acquired drug resistance in TNBC.
  • To discuss innovative therapeutic strategies for overcoming chemoresistance in TNBC.

Main Methods:

  • Literature review synthesizing current research on TNBC drug resistance.
  • Analysis of emerging therapeutic strategies including combination regimens, epigenetic modulators, and natural products.

Main Results:

  • Chemoresistance in TNBC is driven by multifactorial mechanisms including DNA repair, drug efflux, EMT, cancer stem cells, and the tumor microenvironment.
  • Promising strategies involve combining immunotherapy with DNA damage response inhibitors (ATR, WEE1, CHK1), targeting the tumor microenvironment, and eradicating cancer stem cells.

Conclusions:

  • Novel therapeutic approaches, including natural products from traditional Chinese medicine, show potential in reversing TNBC resistance.
  • Integrating mechanistic insights with new treatments is crucial for enhancing treatment durability and improving patient survival in TNBC.